As follow-up of our past publication [1], we propose that quinolones (as part of the pyridinone family) are capable to increase the number of interactions with HIV reverse transcriptase (RT) or integrase (IN) by adding a halogen in position C-8 of aromatic portion of the quinolones. This addition could help with the activity of dual inhibitors of RT and IN. In this work, we add a chlorine atom with the rationale to identify in the docking simulations a halogen interaction with the oxygen in the near aminoacids in the binding pockets of RT and IN enzymes. Our docking studies started with RT and 320 structures. Later, we took 73 structures with good results in docking with RT. The structures that we choose contain ester or acids groups in C-3 due the structural similarity with groups in charge to interact with the Mg ++ ions in Elvitegravir.
Introduction
In our research group we were working with pyridinone derivates as antiretroviral against HIV-1 [1] [2] . This kind of compounds belongs to a family of non-nucleoside reverse transcriptase inhibitors (NNRTI) [3] . In our last publica-Computational Molecular Bioscience tion we could observe that quinolones have big possibilities to be inhibitors of RT and IN [1] . The structures of pyridinone derivates have the possibility to interact with conserved aminoacids in RT to inhibit the activity of the enzyme [4] [5]. Also, the substituents in the pyridinone derivates could interact with Mg ++ ions located in a small space between DNA and IN in the nucleus of the cell. This is to avoid that the enzyme IN blocks the action of DNA as proposed by Wang et al. [6] . The quinolone ring has an aromatic portion facilitating the making of analogues or adding substituents that could contribute to the activity of the compounds. Based on this rationale, here we designed compounds that have in common a chlorine substituent in C-8 of the quinolones and have the basic structure of the pharmacophore published by Freeman et al. [7] . The new structures were designed according with the matrix in Figure 1 . Some structures have ester and acid substituent that could give to the compounds the possibility to be dual inhibitors [6] [8] . Some structures contain a hydroxyl substituent in N-1 in a similar way as is published by Wang et al. [5] . As we can see, the structures show one to three halogens in total but two of the halogens in some of the structures remain in positions C-6 and C-8 of the aromatic ring. It's possible that the chlorine in C-8 position could contribute in the activity of the molecule of quinolone as RT or IN inhibitor due a halogen bond with other aminoacids [9] .
Actually, multi-halogenated compounds belong to the HAART therapy against HIV infection because they are bioactive. As an example of halogenated drugs The objective of this work is to propose new compounds with dual activity against RT and IN which contains halogens that contribute to the activity against HIV-1 and that could reduce the quantity of drugs to be taken orally. The infected persons have to take several pills in a treatment called HAART that have secondary effects. If the quantity of drugs is reduced, the secondary effects will be reduced and will be a benefit to the treated patients [12] .
Methods
Based on the scheme of structures analyzed in our previous publication [1] we propose 320 chemical structures that are synthetically accessible. The goal is to maintain the main structural characteristics of the hybrid pyridinone-UC781
molecule [4] but using the quinolone scaffold according to the matrix of substituent in Figure 2 . In general, the design was constituted by a polar group at C-3
and an unsaturated aliphatic chain in C-4 of the scaffold of quinolone. The scaf- [6] because contain an N-OH substitution.
For the docking studies described below, the crystallographic structures of the biomolecular targets were retrieved from the Protein Data Bank (PDB) (http://www.rcsb.org) [13] . Table 1 summarizes the information of the two structures of RT [14] and one for IN [15] used in this work. The Table 1 
Structure Preparation
This study is a continuation of our previous results published [1] . The same structures were used. The full details of the preparation of the structures are published in Cabrera et al. [1] .
Validation of Docking Protocol
Similar to the previous work [1] before docking of the halogenated structures of the Figure 1 , the docking protocol was validated by re-docking of the co-crystal ligands in their corresponding crystallographic structure. As reference, Table 1 shows the ligands and their respective enzymes used in validation. For this validation were considered semi-flexible the three co-crystal ligands (R165481, R157208 and GS9137) and was done with the MMFF94x force field with the 
3D flexible Alignment of Pyridinone Structures
The flexible alignment of the new quinolones structures was performed to explore if these new structures could adopt similar conformation as the co-crystalized pyridinone analogues. Similar to our previous work, we selected a sample of 10% (32 structures) and each was aligned flexibly to the co-crystal coordinates of R157208 and R165481. For this study, the structure of the co-crystal compound was kept rigid. The docking was conducted with MOE maintaining the default settings (500 iterations in total with 30 consecutive attempts to find the best result) with the MMFF94x force field.
Docking

Docking with RT
For this study, 320 quinolone structures were docked with the crystallographic structures PDB ID: 2BAN and 2B5J [13] and the same settings of the validation were maintained. As result of the docking with the two crystallographic structures, 73 structures were selected to further analysis with IN. In the process of analysis, the protein ligand interaction fingerprints (PLIFs) were important to select the 73 structures. PLIFs were generated with MOE ligand.
Docking with IN
For73 structures were selected based on the similarity with the functional groups and binding poses with known dual inhibitors of RT and IN. The 73 structures were docked with the crystallographic structure PDB ID: 3L2U with the same parameters used in the docking of the crystal ligand (Elvitegravir, GS9137) [15] .
Calculation of Drug-Like Properties
In order to explore the potential oral bioavailability of the structures proposed, we calculated the pharmaceutical properties molecular weight (MW), the partition coefficient octanol/water (Log P) as a measure of lipophilicity, topological polar surface area (TPSA), number of hydrogen bond donors (HBD), number of hydrogen bond acceptors (HBA), and number of rotatable bonds (RB) [17] [18].
Results and Discussion
Alignment of Crystallographic Structures of RT
The coordinates obtained in our previous work [1] of the structures aligned and superposed were used to run the docking using 320 structures of pyridinone derivates. The structures selected for this study were PDB ID: 2BAN and 2B5J [13] .
Validation of the Docking Protocol with RT
Before docking the newly structures proposed in this work (Figure 1 ), the 
Alignment with Co-Crystalized Pyridinone Derivatives
A sample of 10% of the data (32 structures) was taken of the 320 structures in a scheme of stratified random sampling. The structures were aligned flexibly with the position of crystallographic structures of R157208 and R165481 ( Table S1 ). As an example of the alignment, Figure 3 shows the 3D alignment of structures 180 and 270 with R157208 and R165481, Table 2 .
In general, Table 2 
Binding Modes with RT, PDB ID: 2B5J
The results of docking of 320 structures with PDB ID: 2B5J helped us to identify Another interesting interaction that we observed in docking with quinolones 266 and 270 was a halogen interaction between Iodine and Pro236 as is shown in Figure 7 for quinolone 270. The conformation adopted by the ligand enables to contact with Lys101 that is the characteristic interaction of pyridinone.
In the docking performed with PDB ID: 2B5J we could observe less halogen which at same time show interaction with Tyr188 and pro236 with C-4 and C-3 substituents respectively. So, if the interaction with Tyr188 is lost because a mutation the compound could maintain activity against RT because Pro236, which is an aminoacid, conserved.
We found 21 structures that coincide in Table 2 and Table 3 ; this could mean that they have a better probability to be RT inhibitors. Some structures have contact with conserved aminoacids, as Trp229 and Pro236 mentioned by Li et al. [5] which is favorable because this evidence give more probability to think that this contacts could help in the activity of the compounds. In the shown the 21 structures and the aminoacid of contact depending of PDB structure of RT.
Validation of the Docking Protocol with IN
In order to validate the docking with IN, we re-docked the co-crystal ligand in PDB ID: 3L2U (Figure 10 ), Elvitegravir. The binding mode was reproducible by MOE with a RMSD value of 1.3 Å (similar to our previous work [1] ).
Docking with IN
We docked 73 selected quinolone structures that showed key interactions in the docking models with PDB ID: 2BAN and 2B5J, respectively. The docking with IN was done with the structure of IN PDB ID: 3L2U (Structures of quinolones in supplementary material as Figure S1 ). The quinolones have ester or carboxylic acid groups at C-3 and carbonyl group in C-2. Similar to the quinolones, Elvitegravir has a carboxylic acid at C-3 and a carbonyl group at C-4. In Table 5 In Table 5 we can see how quinolone 138 have the best result of score docking (−6.686) with PDB ID: 3L2U and have similar interaction to Elvitegravir with the two Mg ++ ions (Figure 11 ). In the Figure 
Drug-Like Properties
The structures identified as potential compounds with activity against RT and IN were evaluated in base to the rules of Lipinski and Veber, which comprise six pharmacological properties of interest. The pharmacological properties calculated to 73 structures were MW, Log P, HBD and HBA, RB and TPSA. The results are included in supplementary material (Table S2 ).
Conclusions and Perspective
The results of docking with RT reveal in MOE that chlorine in C-8 of the quinolone could has the capacity to interact with Pro236 or Lys103 forming a halogen bond. The most important halogen interaction is with an oxygen atom of the carbonyl group of Pro236. Pro236 is a conserved aminoacid that could contribute to the inhibition activity of RT even help to preserve the activity with 
